Abstract:The detection of mutations in the KRAS gene highly associated with cancer is one of the most widely used Sanger sequencing capillary electrophoresis (CE) applications in molecular diagnostics. In addition to their traditional role in cancer diagnostic, KRAS mutations have recently gained additional relevance as pharmacogenomics (PGx) markers for a significant number of new oncology therapeutics. KRAS mutation detection assays are used as companion diagnostics (CDx) for these cancer treatments. Analysis by Sanger Sequencing of KRAS mutations is cost effective and lends itself for use in resource limited healthcare settings. While there are currently no commercial kits for targeted sequencing of the KRAS mutation hotspots available, the online Applied Biosystems Primer DesignerTM Tool (thermofisher.com) allows standardization of the PCR primer design between labs and repeat orders of the KRAS assays by using these commercially available assay ID numbers. Here we demonstrate the use of Primer Designer KRAS mutation detections assays for mutation in codon 12, 13 and 61 totaling to 8 allele variants. The data was generated on the SeqStudio Flex CE instrument using reference standard DNA as well as DNA extracted from FFPE solid tumor samples. We show accuracy of variant call (OPA 100% (64/64)) and concordance (OPA 98.3% (59/60)) in a side-by-side comparison of the SeqStudio Flex with the legacy Model 3500 Genetic Analyzer instrument using a set of commercially available (Horizon Discovery) KRAS reference DNA samples. Primary solid tumor samples are processed to Fresh Frozen Paraffin Embedded samples (FFPE) for further disease marker evaluation. These samples are stable for long term at ambient temperatures and provide the opportunity to evaluate prospective biomarkers at large scale to understand their potential utility. Discovery Life Sciences has generated a large-scale biorepository of human biospecimen, including FFPE, plasma/sera, buffy coat, and PBMCs. Archival FFPE samples from oncology indications associated with KRAS mutations, such as non-small cell lung cancer and colorectal cancer, were analyzed and identified samples with KRAS mutations, demonstrating the potential diagnostic utility of these assays. Finally, cell-free (cf) DNA from double spun plasma from relevant indications was also successfully evaluated for KRAS mutations, highlighting the potential for these assays in liquid biopsy studies. The study demonstrates the robustness of the Primer Designer KRAS mutation detection sequencing assays using reference standard DNA as well as DNA derived from FFPE DNA and cfDNA from patient derived tumor samples. For Research Use Only. Not for use in diagnostic procedures. Citation Format: Achim Karger, Ami Patel, Kaylee Tseng, Camila Ornelas, Mary Napier, Rod Beck, Kerri Collwell, Shawn Fahl, Carole Bornarth. KRAS mutation detection by Sanger sequencing using the SeqStudio Flex capillary electrophoresis instrument [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6423.

The analytic performance of a TaqMelt PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue (FFPET) samples of colorectal carcinoma (CRC).

Comprehensive Validation of Snapback Primer-Based Melting Curve Analysis to Detect Nucleotide Variation in the Codon 12 and 13 of KRAS Gene

Combining the amplification refractory mutation system and high-resolution melting analysis for KRAS mutation detection in clinical samples

Increased sensitivity of the non-human primate eye to microwave radiation following ophthalmic drug pretreatment.

Abstract 6423: KRAS mutation detection by Sanger sequencing using the SeqStudio Flex capillary electrophoresis instrument

Analysis of KRAS mutations in circulating tumor DNA and colorectal cancer tissue

Rapid and Sensitive Detection of KRAS Mutation after Fast-Cold-pcr Enrichment and High-Resolution Melting Analysis.

Abstract 3298: Two detection methods of clinical KRAS G12C mutation detection for companion diagnostics

RAS testing of colorectal carcinoma—a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group

Differential High-Resolution Melting Analysis for the Detection of K-ras Codons 12 and 13 Mutations in Pancreatic Cancer.

A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction

[What is the contribution of immunoglobulin determination in respiratory diseases in children?].

Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2.

Detection Of Kras Gene Mutations In Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy For Improving Pancreatic Cancer Diagnosis

High Sensitivity Scanning of Colorectal Tumors and Matched Plasma DNA for Mutations in APC, TP53, K‐RAS, and BRAF Genes with a Novel DHPLC Fluorescence Detection Platform

Co-amplification at Lower Denaturation-temperature PCR Combined with Unlabled-probe High-resolution Melting to Detect KRAS Codon 12 and 13 Mutations in Plasma-circulating DNA of Pancreatic Adenocarcinoma Cases

KRAS Mutation Testing in Metastatic Colorectal Cancer.

A Sensitive Assay Enriched with Blue/White Screening to Empower Sequencing Analysis for G > A Hotspot Mutation in Codon 13 of KRAS Gene

Comparative Analysis of Dideoxy Sequencing, the KRAS StripAssay and Pyrosequencing for Detection of KRAS Mutation.

RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer

KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach